Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6 ... a novel IL-6R inhibitor, may be beneficial for the treatment of RA in ...

a humanized monoclonal antibody specific for interleukin-6 (IL-6) that has successfully completed a Phase IIa trial for rheumatoid arthritis. Through the deal, which involves an upfront payment of ...

The RNA inhibitor olpasiran significantly reduces ... on the secretion of the proinflammatory cytokine interleukin-6 or C-reactive protein compared to the placebo group." Dr. Rosenson credits ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

Opens in a new tab or window ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu ... known to be involved in psoriasis and PsA, such as interleukin (IL)-12, IL-23, and type I interferon.

Tocilizumab, a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or DMARDs. A large clinical trial is needed to confirm tocilizumab's ...